A Phase I, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC278 25 mg q.d. and Raltegravir 400 mg b.i.d.
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2012
At a glance
- Drugs Raltegravir; Rilpivirine
- Indications HIV infections
- Focus Pharmacokinetics
- 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
- 23 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.